Moberg Pharma launches new patent pending formulation of Kerasal Nail in the U.S.

STOCKHOLM--()--Regulatory News:

Moberg Pharma AB (STO:MOB) announces that the company this week starts shipping a new patent pending formulation of its market leading product Kerasal Nail™ to U.S. customers.

The new product is shipped as a flow-through and will be available at all existing retailers, including major drugstores CVS, Walgreens and Rite-Aid, mass retailers such as Walmart and Target and leading grocery chains such as Publix and Safeway. Current distribution of Kerasal Nail is estimated to more than 30 000 outlets in the U.S.

Kerasal Nail™ is the market leading product in the OTC fungal nail category with 20% market share in the U.S. as of end 2013. The new formula provides benefits to consumers by improving user-friendliness, facilitating nail penetration and improving stability. Moberg Pharma has applied for patent protection for the new product. The projected expiry date for this new IP is in 2034.

“I am very pleased to announce the launch of the improved formula. The new and improved Kerasal Nail™ demonstrates the value of our development approach, which continues to deliver innovative products with unique benefits to consumers. The new patent application can provide long term IP protection for our lead product”, said Peter Wolpert, CEO of Moberg Pharma AB.

About this information

Moberg Pharma discloses this information pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08.30 am (CET) on March 24, 2014.

About Moberg Pharma AB

Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with its own sales organization in the US and sales through distributors in more than 40 countries. The company’s OTC portfolio includes the brands Kerasal®, Jointflex®, Kerasal Nail™Domeboro®, Vanquish®, Fergon®and Kaprolac®. Kerasal Nail™(Nalox™ in many markets) is the leading product for the treatment of nail disorders in the U.S and Nordic market. The portfolio is developed further through acquisitions and in-licensing of products as well as product development with focus on innovative drug delivery based on proven compounds. Moberg Pharma has offices in Stockholm and New Jersey and the company’s share (OMX: MOB) is listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: www.mobergpharma.se.

This information was brought to you by Cision http://news.cision.com

Contacts

Moberg Pharma AB
Peter Wolpert, CEO
Telephone: +46 707 35 71 35
E-mail: peter.wolpert@mobergpharma.se
or
Peter Östling, IR
Telephone: +46 76 301 09 78
E-mail: peter.ostling@mobergpharma.se

Sharing

Contacts

Moberg Pharma AB
Peter Wolpert, CEO
Telephone: +46 707 35 71 35
E-mail: peter.wolpert@mobergpharma.se
or
Peter Östling, IR
Telephone: +46 76 301 09 78
E-mail: peter.ostling@mobergpharma.se